Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...

Merck and Eisai's experimental combination treatment for a type of kidney cancer met one of the main goals in a late-stage ...

A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in ...

Xencor's clear cell renal cell carcinoma treatment demonstrated evidence of anti-tumor activity in a phase 1 trial.

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but ...

Renal cell carcinoma (RCC) comprises a heterogeneous group of neoplasms with variable prognoses. Chromophobe RCC, a relatively uncommon subtype, generally follows an indolent clinical course but may ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...